Immunic
IMUX
Immunic (IMUX) news
Recent news
Immunic Q2 loss per share USD 0.80
Immunic, Inc. reported a net loss per share of USD 0.80 for the second quarter of 2026, reflecting ongoing financial challenges in its operations [1]. The loss, which was in line with expectations based on the company’s recent guidance, underscores the continued investment in research and…
AInvest Wire · Aug 11, 2026Immunic, Inc. announces private placement of up to $240M
AInvest Wire · Jan 5, 2024ImportantImmunic shares surge 54% in premarket trading on positive interim data from Phase 2 calliper trial of Vidofludimus calcium in progressive multiple sclerosis.
AInvest Wire · Oct 10, 2023ImportantImmunic: Positive interim data from Vidofludimus Calcium trial
AInvest Wire · Oct 9, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.